Request Clinical Starter Kits for Your Patients Today! Request Now

Are you a clinician?

This is a clinician-only website.
By entering, you acknowledge that you're a clinician.

Healthy adults achieve better gut microflora balance with PreticX™ xylooligosaccharides, study shows


  • Randomized, double-blind, placebo-controlled trial with 32 healthy men and women
  • Supplementation consists of 1-2 g/day xylooligosaccharides from PreticX™ for 8 weeks
  • Compared to placebo, supplementing with PreticX™ significantly increases Bifidobacteria in the colon and helps balance gut flora in a dose-dependent manner
  • PreticX™ is well tolerated without gastrointestinal side effects


This double-blind, randomized, placebo-controlled study was designed to evaluate the effects and tolerance of PreticX™ xylooligosaccharides (XOS) on the composition of human colonic microbiota, pH and short chain fatty acids (SCFA) in healthy adults.

For this study, researchers enrolled 32 healthy men and women, aged 21 to 49 years. Participants were randomly assigned to receive one of three supplements: placebo, 1 g/day XOS (from 1.4 g/day PreticX™; 70% XOS) or 2 g/day XOS (from 2.8 g/day PreticX™; 70% XOS) for 8 weeks after a 2-week run-in and followed by a 2-week washout phase. The dosing was twice daily. Stool samples were collected at baseline, week 4, week 8, and 2 weeks after intervention ended. Stool samples were cultured for total bacterial flora, pH and short-chain fatty acid (SCFA) analyses. Pyrosequencing technology (16S rRNA gene-based) was used to assess bacterial diversity with the ability to detect both abundant and rare bacteria in the gut microbiome. Tolerance was evaluated by a daily chart of digestive symptoms graded from 0 (no symptoms) to 3 (severe symptoms). Frequency and consistency of stools were also noted with diarrhea determined as one or more liquid stools or more than 3 stools per day.

Compared to the placebo, the amount of Bifidobacteria significantly increased in both XOS groups with the high-dose group showing significantly (P<.05) greater increases than the low-dose group. Total anaerobic counts and Bacteroides fragilis group counts were also significantly higher in the high-dose XOS group. No significant differences in the amounts of Lactobacillus, Enterobacteriaceae and Clostridium were reported between the three groups. XOS intervention had no significant effect on stool pH, SCFA or lactic acid. Pyrosequencing showed no notable shifts in bacterial diversity. XOS was well tolerated without significant gastrointestinal side effects (e.g., excess flatus, intestinal gurgling, bloating, abdominal pain, or diarrhea).

These findings indicate that supplementing with 1-2 g/day XOS from PreticX™ for 8 weeks significantly increases Bifidobacteria in the colon, helps balance gut flora in a dose-dependent manner, and is well tolerated without gastrointestinal side effects in healthy adults.

PreticX™ is a trademark of AIDP, Inc.


Finegold SM, Li Z, Summanen PH, et al. Xylooligosaccharide increases bifidobacteria but not lactobacilli in human gut microbiota. Food Funct. 2014;5(3):436-45.

PMID: 24513849